Tremelimumab

Drug Profile

Tremelimumab

Alternative Names: CP-675; CP-675,206; Ticilimumab

Latest Information Update: 27 Apr 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Amgen; AstraZeneca; Azienda Ospedaliera Universitaria Senese; Canadian Cancer Trials Group; Fondazione IRCCS Istituto Nazionale dei Tumori; Grupo Espanol de Tumores Neuroendocrinos; Immunocore; Kyoto Breast Cancer Research Network; M. D. Anderson Cancer Center; MedImmune; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); National Health and Medical Research Council; Northwestern University; Pfizer
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer; Mesothelioma; Non-small cell lung cancer
  • Phase II Breast cancer; Endometrial cancer; Gastric cancer; Glioblastoma; Hepatocellular carcinoma; Neuroendocrine tumours; Pancreatic cancer; Prostate cancer; Sarcoma; Small cell lung cancer; Solid tumours
  • Phase I/II Malignant melanoma; Peritoneal cancer
  • Phase I Colorectal cancer; Diffuse large B cell lymphoma; Renal cell carcinoma; Urogenital cancer
  • No development reported Gastrointestinal cancer

Most Recent Events

  • 25 Apr 2017 Memorial Sloan Kettering Cancer Center and AstraZeneca plan a phase I trial for Thyroid cancer (Metastatic disease, Combination therapy, First-line therapy) (NCT03122496)
  • 25 Apr 2017 Memorial Sloan Kettering Cancer Center, MedImmune and AstraZeneca plan a phase II trial for Colorectal cancer (Metastatic disease, Combination therapy) in USA (NCT03122509)
  • 14 Apr 2017 AstraZeneca plans a phase I/II trial for Sarcoma (Combination therapy) in USA (NCT03116529)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top